Comprehensive Summary: Indications for Liver Transplantation
Lecture 1.1 | Prof. Sanjaya Satapathy | Module 1
1. Main Clinical Topics Discussed
- Core indications for liver transplantation (LT)
- The principle of survival benefit as the central determinant for transplantation
- The role and limitations of the MELD score in transplant decision-making
- Indications across three categories: decompensated cirrhosis, acute liver failure (ALF), and selected malignancies
- Common clinical and board examination errors in transplant hepatology
2. Key Learning Points, Guidelines, and Recommendations
Overarching Principle
- LT is indicated when it confers a survival benefit — not simply because cirrhosis or a high MELD score is present
- The central clinical question: *Does transplantation improve survival for this patient right now?*
Decompensated Cirrhosis (Most Common Indication)
- LT is triggered by the onset of decompensation (complications of portal hypertension or liver failure), not by the diagnosis of cirrhosis alone
- First decompensation event is typically the threshold for transplant referral
- What does NOT constitute an indication:
- Compensated cirrhosis (median survival ~13 years before decompensation)
- Elevated liver enzymes in isolation
- Portal hypertension without decompensation
- Radiologically identified cirrhosis without symptoms
MELD Score — Role and Limitations
- MELD predicts short-term mortality and is used for organ allocation, not to determine transplant candidacy
- MELD ≥15: Threshold above which LT confers a survival benefit; below this, surgical risk may outweigh benefit
- MELD does not measure quality of life, determine transplant indication, or capture all high-risk clinical states
Acute Liver Failure
- Constitutes a distinct and urgent indication
- Patients may have a low MELD score yet carry extremely high short-term mortality risk
- No underlying chronic liver disease; rapid progression demands timely decision-making
- Low MELD does not equate to low risk in ALF
Malignancy as Indication (Highly Selected Cases)
- Historically a contraindication; now acceptable under strict, protocol-driven criteria
- Hepatocellular Carcinoma (HCC) — Milan Criteria:
- Single tumor ≤5 cm, OR
- Up to 3 tumors, none >3 cm (range 2–3 cm)
- Other accepted (protocol-driven) indications include:
- Neuroendocrine tumor liver metastases (Mayo Protocol)
- Hilar cholangiocarcinoma (select cases)
- Colorectal liver metastases (very select cases, favorable biology, no extrahepatic disease)
- Absolute contraindication: Active, uncontrolled extrahepatic malignancy
3. Specific Clinical Data and Statistics Cited
- Compensated cirrhosis: median survival of approximately 13 years before decompensation onset
- MELD score of 15: Cited as the critical threshold for transplant survival benefit, supported by multiple studies
- Below MELD 15, transplantation may increase mortality due to perioperative surgical risk
4. Practical Takeaways for Clinicians
- Anchor decision-making to decompensation and survival benefit, not MELD score or diagnosis alone
- Use MELD appropriately: it is an allocation tool, not an indication tool
- Always evaluate whether the patient is compensated vs. decompensated before referral considerations
- In ALF, act urgently regardless of MELD — short-term mortality risk is high and time-sensitive
- For malignancy, apply strict, protocol-driven criteria; look for absence of extrahepatic disease and favorable tumor biology
- Four critical errors to avoid:
1. Equating high MELD alone with transplant indication
2. Equating cirrhosis alone with need for transplant
3. Assuming low MELD excludes transplant benefit (particularly in ALF)
4.